Dengue virus (DENV)
infection is one of the most widely
spread
flavivirus infections. Despite the fatality it could cause, no antiviral
treatment is currently available to treat the disease. Hence, this
study aimed to repurpose old drugs as novel DENV NS3 inhibitors. Ligand-based
(L-B) and proteochemometric (PCM) prediction models were built using
62,354 bioactivity data to screen for potential NS3 inhibitors. Selected
drugs were then subjected to the foci forming unit reduction assay
(FFURA) and protease inhibition assay. Finally, molecular docking
was performed to validate these results. The
in silico
studies revealed that both models performed well in the internal
and external validations. However, the L-B model showed better accuracy
in the external validation in terms of its sensitivity (0.671). In
the
in vitro
validation, all drugs (zileuton, trimethadione,
and linalool) were able to moderately inhibit the viral activities
at the highest concentration tested. Zileuton showed comparable results
with linalool when tested at 2 mM against the DENV NS3 protease, with
a reduction of protease activity at 17.89 and 18.42%, respectively.
Two new compounds were also proposed through the combination of the
selected drugs, which are ziltri (zilueton + trimethadione) and zilool
(zileuton + linalool). The molecular docking study confirms the
in vitro
observations where all drugs and proposed compounds
were able to achieve binding affinity ≥ −4.1 kcal/mol,
with ziltri showing the highest affinity at −7.7 kcal/mol,
surpassing the control, panduratin A. The occupation of both S1 and
S2 subpockets of NS2B-NS3 may be essential and a reason for the lower
binding energy shown by the proposed compounds compared to the screened
drugs. Based on the results, this study provided five potential new
lead compounds (ziltri, zilool, zileuton, linalool, and trimethadione)
for DENV that could be modified further.